HAI Diagnostics Market Reviewed by Kalorama Information in New Report Now Available at MarketPublishers.com

<0> The Market Publishers, Ltd.Tanya RezlerTel: +44 208 144 6009Fax: +44 207 900 3970 </0>

The most common hospital-acquired (HAI) infections, or nosocomial infections, interfering with treatment include methicillin-sensitive Staphylococcus aureus (MRSA), tuberculosis and urinary tract infections. With 5% of the nearly 40 million hospital visits a year resulting in a , nearly 100,000 people die each year from nosocomial infections, a fifth of these from MRSA alone. In the intensive care unit (ICU), where infection is most harmful due to the compromised status of patients, community-acquired pneumonia is a growing problem.

New market research report drawn up by Kalorama Information provides an in-depth discussion on the status of the field of HAI diagnostics as a setting-specific field of application. It reveals developments in this area, provides market size and epidemiological data, and profiles the leading players. The study also presents segmented market data for molecular and conventional testing, covers the development of new testing systems and products, besides providing an analysis of growing drug resistance.

Companies profiled in the report include: Abbott Laboratories; Alere; Becton, Dickinson; bioMerieux; Cephei; Gen-Probe; Meridian Bioscience, Inc.; Qiagen GmbH; Roche; and Siemens AG.


Published: August, 2012

Pages: 117

Price: US$ 3,995.00

More new research reports by Kalorama Informationcan be found at